Disease-modifying therapies should be stopped in NMOSD patients in remission – Yes
نویسندگان
چکیده
منابع مشابه
Vaccination against polio should not be stopped
| The striking 50-year-long decline in the incidence of poliomyelitis has stalled in the past 7 years, which has led to calls for an urgent re-assessment of eradication and post-eradication campaign strategies. The current plan of eliminating the circulation of wild poliovirus so that further immunization will be unnecessary does not take into account recent scientific data and political realit...
متن کامل[Can the medication in patients with rheumatoidarthritis in remission be stopped?].
Rheumatoid arthritis is a chronic systemic inflammatory disease that causes significant morbidity and mortality. The combined use of methotrexate and biological agents directed against tumor necrosis factor (TNF) has achieved significant improvement in clinical, radiographic and functional parameters not seen previously and has revolutionized the therapeutic goal of achieving remission in clini...
متن کاملYes, Managers Should Be Paid like Bureaucrats
Corporate scandals, reflected in excessive management compensation and fraudulent accounts, cause considerable damage. Agency theory’s insistence on linking the compensation of managers and directors as closely as possible to firm performance is a major reason for these scandals. They cannot be overcome by improving variable pay for performance, as selfish extrinsic motivation is reinforced. Ba...
متن کاملEmerging oral disease-modifying therapies
Over the last two decades, patients have relied on the use of self-injectable disease modifying agents for the treatment of multiple sclerosis. The need for frequent injections has affected treatment up take and adherence. Fingolimod, the first oral disease modifying agent to be licensed in Europe and the United States, has been shown to be effective in reducing relapse rates in comparison to p...
متن کاملShould the target A1C level be less than 7 percent? Yes: This should be the target for most patients.
In 1993, the DCCT (Diabetes Control and Complications Trial) demonstrated that better glycemic control reduces microvascular disease in patients with type 1 diabetes mellitus.1 Ten years later, the EDIC (Epidemiology of Diabetes Interventions and Complications) trial established that macrovascular disease was also reduced by the DCCT.2 In 1998, the UKPDS (United Kingdom Prospective Diabetes Stu...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: Multiple Sclerosis Journal
سال: 2019
ISSN: 1352-4585,1477-0970
DOI: 10.1177/1352458519829694